Be The Match BioTherapies, an organization offering services for companies developing and commercializing cell and gene therapies, entered a partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies. Be The Match BioTherapies will supply an extensive cell therapy infrastructure that provides Garuda with regulatory compliant starting material.
  
To support the development of Garuda’s approach, Be The Match BioTherapies will provide bioinformatics consulting, source difficult-to-find donors, regulatory support, protocol and post-collection processing needs, and supply chain logistics.
 
This collaboration aims to further Garuda’s platform for generation of off-the-shelf, self-renewing blood stem cells towards the clinic as potential treatment for patients with hematological diseases. 
 
“Our passionate goal of delivering life-changing cellular therapeutics to patients around the world necessitates stringent criteria for starting material including highly-specific HLA haplotype donors,” said Dhvanit Shah, Founder, President, & CEO of Garuda. “The vast donor registry, expertise in collection, and provision of cellular starting materials, makes Be The Match BioTherapies an ideal partner to enable Garuda to source the donors needed to advance our efforts to generate off-the-shelf, self-renewing blood stem cells.”
 
“We are proud to partner with Garuda and support their development of these potentially life changing therapies,” said Chris McClain, Senior Vice President Sales and Business Development at Be The Match BioTherapies. “Together we have the opportunity to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies with the potential to address, and possibly cure, more than 120 diseases.”